Running head: SARS-CoV-2 screening considerations 27 January 2022

1 Screening for SARS-CoV-2 in close contacts of individuals with confirmed

2 infection: performance and operational considerations

- 3 Stephanie Zobrist^{1*#}, Michelle Oliveira-Silva^{2#}, Alexia Martines Vieira², Pooja Bansil¹, Emily Gerth-
- 4 Guyette¹, Brandon T. Leader¹, Allison Golden¹, Hannah Slater¹, Catherine Duran de Lucena Cruz²,
- 5 Eduardo Garbin², Mariana Sagalovsky¹, Sampa Pal¹, Vin Gupta³, Leo Wolansky⁴, Deusilene Souza Vieira
- 6 Dall'Acqua⁵, Felipe Gomes Naveca⁶, Valdinete Alves do Nascimento⁶, Juan Miguel Villalobos Salcedo⁵,
- 7 Paul K. Drain⁷, Alexandre Dias Tavares Costa⁸, Gonzalo J Domingo¹, Dhélio Pereira²

8 Affiliations:

- 9 1. Diagnostics, PATH, Seattle, Washington, United States
- 10 2. Centro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil
- 11 3. Amazon.com, Seattle, Washington, United States
- 12 4. The Rockefeller Foundation, Pandemic Prevention Institute, New York City, New York, United
- 13 States
- 14 5. Fundação Oswaldo Cruz (FIOCRUZ), Porto Velho, Rondônia, Brazil
- 15 6. Instituto Leônidas e Maria Deane (ILMD), Fundação Oswaldo Cruz (FIOCRUZ), Manaus,
- 16 Amazonas, Brazil
- Departments of Global Health and Medicine, University of Washington, Seattle, Washington, United
 States
- 19 8. Instituto Carlos Chagas (ICC), Fundação Oswaldo Cruz (FIOCRUZ), Curitiba, Paraná, Brazil
- 20 *Corresponding author. Stephanie Zobrist, Tel: 206-285-3500, Email: szobrist@path.org
- [#]These authors contributed equally to this work.
- 22 Running head: SARS-CoV-2 screening considerations

Running head: SARS-CoV-2 screening considerations 27 January 2022

23 Footnotes

- 24 Conflict of Interest Statement
- 25 The authors declare no conflicts of interest.
- 26 Funding Statement
- 27 This study was funded by The Rockefeller Foundation and Amazon.com.
- 28 Corresponding Author Contact Information
- 29 Stephanie Zobrist
- 30 2201 Westlake Avenue, Suite 200
- 31 Seattle, WA, USA 98121
- 32 Tel: 206-285-3500
- 33 Email: <u>szobrist@path.org</u>

Running head: SARS-CoV-2 screening considerations 27 January 2022

34 Abstract

- 35 Background. Point-of-care and decentralized testing for SARS-CoV-2 is critical to inform public health
- 36 responses. Performance evaluations in priority use cases such as contact tracing can highlight trade-offs in
- 37 test selection and testing strategies.
- 38 *Methods*. A prospective diagnostic accuracy study was conducted among close contacts of COVID-19
- 39 cases in Brazil. Two anterior nares swabs (ANS), a nasopharyngeal swab (NPS), and saliva were
- 40 collected at all visits. Vaccination history and symptoms were assessed. Household contacts were
- 41 followed longitudinally. Three rapid antigen tests and one molecular method were evaluated for usability
- 42 and performance against reference RT-PCR on NPS.
- 43 Results. Fifty index cases and 214 contacts (64 household) were enrolled. Sixty-five contacts were RT-
- 44 PCR positive during at least one visit. Vaccination did not influence viral load. Gamma variants were
- 45 most prevalent; Delta emerged increasingly during implementation. Overall sensitivity of evaluated tests
- 46 ranged from 33%–76%. Performance was higher among symptomatic cases and cases with Ct<34 and
- 47 lower among oligo/asymptomatic cases. Assuming a 24-hour time-to-result for RT-PCR, the cumulative
- 48 sensitivity of an ANS rapid antigen test was >70% and almost 90% after four days.
- 49 *Conclusions.* The near immediate time-to-result for antigen tests significantly offsets lower analytical
- 50 sensitivity in settings where RT-PCR results are delayed or unavailable.
- 51 Keywords: Porto Velho, Rondônia, Allplex[™] SARS-CoV-2 Assay, SalivaDirect, SD Biosensor
- 52 STANDARD Q COVID-19 Ag, LumiraDx SARS-CoV-2 Ag Test

Running head: SARS-CoV-2 screening considerations 27 January 2022

53 Introduction

54 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which causes COVID-19, has

significantly burdened health systems globally, with over 22 million confirmed cases in Brazil alone as of

56 2021 [1]. A key challenge of the pandemic response is access to appropriate diagnostic testing, which is

57 critical to inform public health strategies [2].

58 The reference standard for SARS-CoV-2 testing is RT-PCR. While accurate, this method has many

59 practical limitations, including cost, laboratory infrastructure requirements, and often invasive sampling.

60 RT-PCR testing is typically centralized, which can lead to delays in reporting results to patients. Such

61 delays have important public health implications, including increased risk for transmission during the

62 period before results are available [3,4]. Expanded access to decentralized and point-of-care (POC)

testing is essential to identify cases early and limit community transmission, particularly where RT-PCR

64 is unavailable.

65 Infected persons both with and without symptoms can transmit SARS-CoV-2 [5–7]. Due to the

66 significance of asymptomatic transmission [8], testing these populations is often recommended, including

67 close contacts of individuals with confirmed infection as part of contact tracing, testing, and isolation

68 strategies [9,10].

69 Multiple platforms have been developed to enable decentralized and POC SARS-CoV-2 testing [11]. In

70 particular, rapid antigen tests have garnered interest due to their lower cost, ease of use, and rapid

turnaround time for results (typically <30 minutes) [10, 12]. The World Health Organization (WHO)

72 advises that rapid antigen tests meeting minimum performance criteria can be employed in a range of use

cases, including for testing of asymptomatic contacts of cases [10]. Previous performance evaluations

have shown variability, with strongest performance among symptomatic individuals with high viral loads

in early stages of infection [11, 13–15]. Several studies have investigated test performance among

contacts of confirmed cases [16,17]; however, more data are needed to understand trade-offs in test

Running head: SARS-CoV-2 screening considerations 27 January 2022

- selection and inform screening strategies regarding the timing and frequency of testing and performance
- 78 characteristics.

79 Methods

80 Study design and population

81 A prospective diagnostic accuracy study was conducted among close contacts of COVID-19-positive 82 index cases in Porto Velho, Brazil, between July and September 2021. Symptomatic adults within seven days of symptom onset who tested positive on a rapid SARS-CoV-2 antigen test (STANDARD Q 83 84 COVID-19 Ag Nasal Test, SD Biosensor, Republic of Korea) were recruited as index cases. Close 85 contacts were identified through interviews administered at enrollment of the index case. Individuals 12 86 years of age or older who resided in Porto Velho were eligible for inclusion as close contacts if they met 87 one or more of Brazil's criteria within the investigation period of the index case (two days prior to 88 symptom onset to the time of the interview) (Supplementary Material A) [18]. Contacts with prior 89 positive COVID-19 test results within the past three months were not eligible. A subset of household 90 contacts (who shared a primary residence with the index case) had serial visits for clinical evaluations and 91 testing every other day over nine days.

92 **Tests evaluated**

93 This study evaluated four SARS-CoV-2 tests: the STANDARD Q COVID-19 Ag Nasal and Saliva tests,

94 the SARS-CoV-2 Ag Test (LumiraDx[™] Limited, United Kingdom), and the SalivaDirect[™] protocol

95 (Yale School of Public Health, United States). The STANDARD Q tests are rapid chromatographic

- 96 immunoassays for qualitative detection of antigens from SARS-CoV-2 in human nasal and saliva
- 97 specimens, respectively. The LumiraDx test is a microfluidic immunofluorescence assay for qualitative
- 98 detection of antigen in nasal specimens [19–24]. SalivaDirect is a dual-plexed RT-PCR method for
- 99 SARS-CoV-2 detection from minimally processed saliva [25,26].

Running head: SARS-CoV-2 screening considerations 27 January 2022

100 Study procedures at the point of care

- 101 At enrollment, information on participant demographics, health status, and medical history were
- 102 collected. Presence, duration, and severity of symptoms were assessed at all visits, and two paired anterior
- 103 nares swabs (ANS), one nasopharyngeal swab (NPS), and saliva were collected (Supplementary Material
- 104 B). One ANS was used to run the STANDARD Q COVID-19 Ag Nasal Test during the visit. All
- specimens were then transferred to a laboratory where the remaining tests were performed.
- 106 For household contacts in the longitudinal sample, if the POC screening test was positive, only one
- 107 additional study visit occurred, during which NPS were not collected to minimize staff exposure.
- 108 Participants were considered lost to follow-up after two missed visits.

109 Laboratory procedures

- 110 The extracted ANS mixed with LumiraDx buffer was frozen within five hours of collection and thawed
- 111 before testing, no more than five days after freezing. The saliva sample was also frozen; aliquots were
- 112 thawed for testing with the STANDARD Q COVID-19 Ag Saliva Test (within five days of freezing) and
- 113 SalivaDirect. Evaluated tests were conducted per manufacturer instructions and by operators blinded to
- 114 close contact POC and reference results.
- 115 *Reference testing.* NPS were used for reference testing with the Allplex[™] SARS-CoV-2 Assay (Seegene
- 116 Inc., Republic of Korea), a multiplex real-time PCR assay, on a CFX96 real-time PCR machine (Bio-Rad,
- 117 United States) [27]. Automated RNA extraction was conducted using the Loccus Extracta kit (Loccus,
- 118 Brazil). All SARS-CoV-2-positive specimens were repeated on the same assay for quantitative estimation
- 119 of viral load. Specimens with cycle threshold (Ct) values <30 underwent genomic sequencing
- 120 (Supplementary Material C). Staff conducting reference testing were blinded to other close contact test
- 121 results.

122 Usability assessment

Running head: SARS-CoV-2 screening considerations 27 January 2022

123 Study staff responsible for use of the antigen tests were invited to participate in a usability assessment. A

- 124 System Usability Scale (SUS) was employed, and an Ease of Use (EoU) questionnaire was adapted
- 125 [21,28] (Supplementary Material D). SUS scores above 68 were considered acceptable [29,30]. To
- 126 analyze data from the EoU questionnaire, a matrix was used to rank aspects of the products' usability as
- 127 "satisfactory," "average," or "unsatisfactory" (Supplementary Material E) [21].

128 Sample size and statistical analysis

129 The sample size targeted at least 50 contacts with a positive reference result, including at least 20

asymptomatic individuals, to meet US FDA Emergency Use Authorization requirements [31].

131 Participants with no symptoms at the time of sampling were classified as asymptomatic. Participants were

132 considered symptomatic if they presented with cough, shortness of breath, difficulty breathing, or at least

133 two of the following symptoms at the time of sampling: fever, chills, rigor, myalgia, headache, sore

throat, new olfactory or taste disorder [32]. Participants who presented with one or more mild symptoms

135 but did not fit the symptomatic case definition and reported no care seeking or changes to behavior were

136 considered oligosymptomatic.

137 Sensitivity, specificity, and positive and negative predictive values were calculated using standard

138 formulas and presented with 95% CIs. Samples for which both RT-PCR and evaluated test results were

139 available were included in the analysis. Using the longitudinal dataset, trade-offs between performance

and utility of the evaluated tests in terms of cumulative sensitivity at specified time points were assessedas a function of time-to-results.

142 Data were collected and managed using REDCap electronic data capture tools hosted at the Institute of

- 143 Translational Health Sciences [33]. Statistical analyses were conducted using Stata 15.0 (StataCorp,
- 144 College Station, Texas, USA) and R 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

145 **Ethical considerations**

Running head: SARS-CoV-2 screening considerations 27 January 2022

- 146 WCG Institutional Review Board (1301165), the CEPEM ethics committee, and Brazil's National
- 147 Research Ethics Commission approved this study (44351421.0.0000.0011). Written informed consent
- 148 was obtained for all participants. Minors under 18 provided assent, and written informed consent was
- 149 obtained from parents/legal guardians.

150 **Results**

151 **Participant characteristics**

- 152 Fifty symptomatic COVID-19-positive index cases and 214 of their associated close contacts were
- 153 enrolled (Table 1). Sixty-four contacts shared a primary residence with an index case and were therefore
- 154 included in the longitudinal sample. Contacts ranged from ages 13 to 79. The majority of participants
- across all groups were female. Sixty-five contacts (30%, 65/214) were SARS-CoV-2 positive by the
- 156 reference assay during at least one visit (Figure 1). For household contacts, positivity rates and symptom
- 157 status varied by visit. In total, 42 paired samples were collected at unique visits with oligo/asymptomatic
- 158 positive contacts, from 32 participants.

159 Vaccination status

- 160 Most participants were either partially (45%, 118/264) or fully (27%, 70/264) vaccinated at enrollment
- 161 (Table 1). No statistical difference was observed in viral loads between vaccinated and unvaccinated
- 162 individuals (Figure 2; Supplementary Material F, G).

163 Sequencing

- 164 Sequences were available for 84 positive samples: 68 Gamma (P.1, P.1.4, and P.1.7), and 16 Delta
- 165 (AY.36, AY.4, AY.43, AY.99.2), with seven total lineages. The Delta strain became more prevalent
- among samples collected later in the study (Supplementary Material H).

167 Diagnostic performance

Running head: SARS-CoV-2 screening considerations 27 January 2022

- 168 The two POC ANS antigen tests demonstrated comparable performance, with overall sensitivity of 55.0%
- 169 for the STANDARD Q (95% CI 43.5%–66.2%) and 50.6% for LumiraDx (95% CI 39.1%–62.1%) (Table
- 170 2). Performance increased to >80% sensitivity for both tests among symptomatic cases but decreased to
- 171 <30% among oligo/asymptomatic cases. For specimens with Ct values less than 34, above which viral
- 172 viability is negligent and quantification is not as reliable [34,35], performance of both tests improved,
- 173 with sensitivities in the ranges of 90% and 60% for symptomatic and oligo/asymptomatic cases,
- 174 respectively.
- 175 The SalivaDirect PCR assay showed the highest overall performance at 75.9% sensitivity (95% CI
- 176 65.0%–84.9%), which increased to 90.0% (95% CI 78.2%–96.7%) among contacts with Ct<34. In all
- scenarios, the rapid STANDARD Q Saliva Test had a sensitivity of <53%.
- 178 Figure 3 presents the viral load of positive specimens, stratified by results of the STANDARD Q Nasal
- and Saliva tests. Overall, specimens with low viral loads were more likely to yield negative results;
- 180 however, misclassification of specimens with high viral loads was more common with the saliva test.

181 Longitudinal analysis

- 182 To investigate how test results changed over time, descriptive grid plots were generated for all household 183 contacts with a positive reference result at any timepoint (Supplementary Material I). Figure 4 includes 184 two examples of overall patterns in the dataset.
- 185 The time-to-positivity from days since enrollment for close contacts with a positive reference result
- 186 (Ct<34) at any timepoint was assessed by comparing the proportion of participants with positive results
- 187 by reference RT-PCR and a POC ANS antigen test (STANDARD Q Nasal) under different scenarios for
- 188 RT-PCR result turnaround time (Figure 5). Even with a relatively rapid RT-PCR result turnaround of 24
- 189 hours, >70% of contacts would have been identified by a POC test. At 48 hours, cumulative sensitivity is
- 190 80%, increasing to nearly 90% at four days.

191 Usability

Running head: SARS-CoV-2 screening considerations 27 January 2022

- 192 In total, 12 study staff completed the usability assessment. All three POC antigen tests were considered
- 193 easy to use and SUS scores were acceptable (>77) (Supplementary Material J).

194 **Discussion**

195 In this study, performances of three POC antigen tests (two ANS and one saliva) and one molecular saliva

196 assay were assessed among close contacts of COVID-19-positive index cases. All tests demonstrated

197 strongest performance among symptomatic cases—and particularly those with Ct<34. Performance

decreased among oligo/asymptomatic cases, which is consistent with results of prior studies [11,13] and

199 may indicate that the tests are best able to detect those most likely to be infectious [34,35]. However,

200 there is no universal Ct value cut-off-point that corresponds to infectivity, and the relationship between Ct

201 values and viral load varies by laboratory [11].

202 The SalivaDirect assay had the best performance, with sensitivity of up to 90% among contacts with

203 Ct<34. Although this assay uses a noninvasive sample type and a simplified procedure that minimizes

204 processing time and costs, infrastructure and training requirements still limit the feasibility of

205 implementing this test in many settings, with potential implications for time-to-results.

206 The saliva antigen test had the lowest overall performance, consistent with the findings of other

207 evaluations of POC saliva antigen tests [36,37]. One recent evaluation of this test reported an overall

sensitivity of 66.1%; however, the reference assay was conducted on saliva [38]. In this study, the test

209 was run on passively collected saliva. This may have impacted performance, as the manufacturer

210 recommends use of actively collected saliva with snorted nasal mucus.

212 performance which was best among cases with Ct<34. Among symptomatic cases and those with Ct<34,

both tests met WHO performance criteria ($\geq 80\%$ sensitivity and $\geq 97\%$ specificity) [10]. Both tests were

also considered easy to use; however, the LumiraDx test requires use of an instrument.

²¹¹ The two POC ANS antigen tests—STANDARD Q Nasal and LumiraDx—demonstrated comparable

Running head: SARS-CoV-2 screening considerations 27 January 2022

215 Overall, the observed positivity rate among close contacts (65/214, 30%) highlights the importance of 216 contact tracing and testing as a public health strategy [39]. The longitudinal data demonstrate the value of 217 serial testing (particularly for individuals with known exposures) and the practical benefits of timely 218 results [40, 41]. In this study, we show that in settings where RT-PCR is unavailable or where time-to-219 results is >4 days, close to 90% of individuals with Ct<34 could benefit from an earlier result via a POC 220 test. Even in settings where RT-PCR results are available within 24 hours, cumulative sensitivity of a 221 POC test is >70%. With repeat serial testing over a period of 9 days, the cumulative sensitivity of a POC 222 ANS antigen test increases from 70% to near 90%. In many settings, limited RT-PCR testing capacity— 223 especially during high demand—can lead to delays in results. Immediate results can impact behavior of 224 potentially infectious individuals, encouraging earlier isolation and signaling where additional testing is 225 warranted [4]. The emergence of antiviral therapies—which are more effective the sooner they are 226 taken—further underscores the value of timely results.

227 Limitations

228 Limitations of the study include its modest sample size, reflected in the 95% Cis reported with

229 performance indicators. Further, the STANDARD Q Nasal and LumiraDx tests are among the best-in-

230 class commercial POC antigen tests. Other tests with lower performance may increase the risk of missing

231 infections against the benefit of identifying cases, to the extent that other strategies may be needed if RT-

232 PCR is unavailable. Lastly, future research should investigate implications of new variants on diagnostic

233 performance across sample types.

234 Conclusion

235 The near immediate time-to-result of rapid antigen tests is a significant benefit that offsets reduced

sensitivity by decreasing diagnostic delays and onward viral transmission. Here, we demonstrate that

237 POC ANS antigen tests for SARS-CoV-2 are easy to use and perform adequately to provide prompt,

actionable information to both the health system and individuals.

11

Running head: SARS-CoV-2 screening considerations 27 January 2022

239 Funding

- 240 This work was supported by grants from The Rockefeller Foundation [2020 HTH 039] and Amazon.com
- 241 [2D-04020007] to GJD. REDCap hosted at the Institute of Translational Health Sciences is supported by
- 242 the National Center For Advancing Translational Sciences of the National Institutes of Health under
- Award Number UL1 TR002319. FGN and VAN were supported by the National Council for Scientific
- and Technological Development [grant 403276/2020-9] and Inova Fiocruz/Fundação Oswaldo Cruz
- 245 [grant VPPCB-007-FIO-18-2-30 Knowledge generation]. FGN is a CNPq fellow.

246 Acknowledgements

- 247 The authors would like to thank all study participants as well as the clinical and laboratory staff at
- 248 CEPEM involved with this study. We also thank SD Biosensor and LumiraDx for facilitating the
- 249 availability of their tests for this study. Finally, we also thank Amanda Tsang and Christine Waresak for

editorial support with the manuscript.

Running head: SARS-CoV-2 screening considerations 27 January 2022

251 Tables

252 **Table 1. Characteristics of study participants.**

Characteristic	Index cases (N=50)	Close contacts, non-household (N=150)	Close contacts, household (N=64)
Age			
Mean (SD)	40.1 (12.8)	38.4 (14.6)	34.7 (17.2)
Range	19–68	13–86	14–79
Sex*, n (%)			
Female	32 (64.0)	81 (54.0)	37 (57.8)
Male	18 (36.0)	69 (46.0)	27 (42.2)
Vaccination status**, n (%)			
Fully vaccinated	12 (24.0)	43 (28.7)	15 (23.4)
Partially vaccinated	24 (48.0)	69 (46.0)	25 (39.0)
Unvaccinated	14 (28.0)	38 (25.3)	24 (37.5)
Vaccine type, n (%)			
AstraZeneca	19 (52.8)	47 (42.0)	11 (27.5)
CoronaVac	9 (25.0)	28 (25.0)	10 (25.0)
Johnson & Johnson	2 (5.6)	4 (3.6)	0 (0)
Pfizer	6 (16.7)	33 (29.5)	19 (47.5)
Relationship to index case, n (%)			
Family (same household)	-	0 (0)	64 (100.0)
Family (other household)	-	45 (29.3)	-
Neighbor	-	7 (4.7)	-
Friend	-	49 (32.7)	-

Running head: SARS-CoV-2 screening considerations

27 January 2022

Coworker	-	41 (27.3)	-
Classmate	-	4 (2.7)	-
Other	-	4 (2.7)	-
Duration of estimated exposure, n (%)			
15 minutes to 1 hour	-	30 (20.0)	-
1 to 3 hours	-	41 (27.3)	-
3 to 8 hours	-	68 (45.3)	-
8+ hours	-	11 (7.4)	64 (100.0)
Location of exposure, n (%)			
Home	-	84 (56.0)	64 (100.0)
Work	-	47 (31.3)	-
Social setting	-	15 (10.0)	-
Other	_	4 (2.7)	

²⁵³

* No statistical differences were observed by sex in any of the three groups, using a t-test.

254 ** Fully vaccinated classification indicates that a participant had received all required vaccine doses and was >14 days since

255 receipt of the last vaccine dose at enrollment.

- 256 Table 2. Performance indicators for tests evaluated using nasopharyngeal RT-PCR as the reference standard. Performance is shown
- across all close contacts and those with PCR Ct values of less than 34. Tests with black headers were run on anterior nares swabs, and tests
- 258 with grey headers were run on saliva.

	All close contacts (Household and non-household)			Close contacts (Ct<34) (Household and non-household)			
	Overall	Symptomatic positive	Oligo/asymptomatic	Overall	Symptomatic positive	Oligo/asymptomatic	
STANDARD Q Nasal, n	343	38	42	313	34	16	
Sensitivity (95% CI)	55.0 (43.5–66.2)	84.2 (68.8–94.0)	28.5 (15.7–44.6)	84.0 (70.9–92.8)	91.2 (76.3–98.1)	68.8 (41.3–89.0)	
Specificity (95% CI)	100.0 (98.6–100.0)	N/A	N/A	100.0 (98.6–100.0)	N/A	N/A	
PPV (95% CI)	100.0 (92.0–100.0)	N/A	N/A	100.0 (91.6–100.0)	N/A	N/A	
NPV (95% CI)	88.0 (83.7–91.4)	N/A	N/A	97.0 (94.3–98.7)	N/A	N/A	
LumiraDx Nasal, n	345	37	42	315	33	16	
Sensitivity (95% CI)	50.6 (39.1-62.1)	81.1 (64.8–92.0)	23.8 (12.1–39.5)	79.6 (65.7–89.8)	87.9 (71.8–96.6)	62.5 (35.4–84.8)	
Specificity (95% CI)	100.0 (98.6–100.0)	N/A	N/A	100.0 (98.6–100.0)	N/A	N/A	
PPV (95% CI)	100.0 (91.2–100.0)	N/A	N/A	100.0 (91.0–100.0)	N/A	N/A	
NPV (95% CI)	87.2 (82.9–90.7)	N/A	N/A	96.4 (93.4–98.2)	N/A	N/A	
STANDARD Q Saliva, n	340	38	42	310	34	16	
Sensitivity (95% CI)	32.5 (22.4–43.9)	50.0 (33.4–66.6)	16.7 (7.0–31.4)	48.0 (33.7–62.6)	52.9 (35.1–70.2)	37.5 (15.2–64.5)	
Specificity (95% CI)	98.8 (96.7–99.8)	N/A	N/A	98.8 (96.7–99.8)	N/A	N/A	

Running head: SARS-CoV-2 screening considerations

27 January 2022

89.7 (72.6–97.8)	N/A	N/A	88.9 (70.8–97.6)	N/A	N/A
82.6 (78.0-86.7)	N/A	N/A	90.8 (86.8–93.9)	N/A	N/A
339	38	41	310	34	16
75.9 (65.0–84.9)	89.5 (75.2–97.1)	63.4 (46.9–77.9)	90.0 (78.2–96.7)	94.1 (80.3–99.3)	81.3 (54.4–96.0)
97.7 (95.0–99.1)	N/A	N/A	97.7 (95.0–99.1)	N/A	N/A
90.9 (81.3–96.6)	N/A	N/A	88.2 (76.1–95.6)	N/A	N/A
93.0 (89.3–95.8)	N/A	N/A	98.1 (95.6–99.4)	N/A	N/A
	82.6 (78.0–86.7) 339 75.9 (65.0–84.9) 97.7 (95.0–99.1) 90.9 (81.3–96.6)	82.6 (78.0–86.7) N/A 339 38 75.9 (65.0–84.9) 89.5 (75.2–97.1) 97.7 (95.0–99.1) N/A 90.9 (81.3–96.6) N/A	82.6 (78.0–86.7) N/A N/A 339 38 41 75.9 (65.0–84.9) 89.5 (75.2–97.1) 63.4 (46.9–77.9) 97.7 (95.0–99.1) N/A N/A 90.9 (81.3–96.6) N/A N/A	82.6 (78.0–86.7) N/A N/A 90.8 (86.8–93.9) 339 38 41 310 75.9 (65.0–84.9) 89.5 (75.2–97.1) 63.4 (46.9–77.9) 90.0 (78.2–96.7) 97.7 (95.0–99.1) N/A N/A 97.7 (95.0–99.1) 90.9 (81.3–96.6) N/A N/A 88.2 (76.1–95.6)	82.6 (78.0–86.7) N/A N/A 90.8 (86.8–93.9) N/A 339 38 41 310 34 75.9 (65.0–84.9) 89.5 (75.2–97.1) 63.4 (46.9–77.9) 90.0 (78.2–96.7) 94.1 (80.3–99.3) 97.7 (95.0–99.1) N/A N/A 97.7 (95.0–99.1) N/A 90.9 (81.3–96.6) N/A N/A 88.2 (76.1–95.6) N/A

259

CI: confidence interval; Ct: cycle threshold; PPV: positive predictive value; NPV: negative predictive value; N/A: not applicable; RT-PCR: reverse transcription-polymerase chain reaction

Running head: SARS-CoV-2 screening considerations 27 January 2022

260 **References**

- Ministry of Health Health Surveillance Secretariat. Special Epidemiological Bulletin: Coronavirus Disease COVID-19. 10 December 2021. Available at: <u>https://www.gov.br/saude/pt-br/media/pdf/2021/dezembro/11/boletim_epidemiologico_covid_92_10dez21.pdf</u>.
- Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol 2021; 19(3):171-183. doi:10.1038/s41579-020-00461-z.
- Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wijgert JHHM, Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. Lancet Public Health 2020 ; 5(8):e452-e459. doi:10.1016/S2468-2667(20)30157-2.
- 4. Larremore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv 2021; 7(1):eabd5393.
 doi:10.1126/sciadv.abd5393.
- Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Proc Natl Acad Sci U S A 2021 ; 118(34):e2109229118. doi:10.1073/pnas.2109229118.
- Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and metaanalysis. PLoS Med 2020; 17(9):e1003346. doi:10.1371/journal.pmed.1003346.
- Byambasuren O, Cardona M, Bell K, et al. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. JAMMI 2020 ; 5(4): 223–234. doi: 10.3138/jammi-2020-0030.
- Qiu X, Nergiz AI, Maraolo AE, et al. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission- a living systematic review. Clin Microbiol Infect 2021; 27(4): 511– 519. doi: 10.1016/j.cmi.2021.01.011.


- Fiore VG, DeFelice N, Glicksberg BS, et al. Containment of COVID-19: Simulating the impact of different policies and testing capacities for contact tracing, testing, and isolation. PLoS One 2021 ; 16(3):e0247614. doi:10.1371/journal.pone.0247614.
- 10. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection. Interim Guidance. 6 October 2021. Geneva; WHO. Available at: <u>https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays</u>.
- Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2020 ; 8(8):CD013705. doi:10.1002/14651858.CD013705.
- Drain P. Rapid diagnostic testing for SARS-CoV-2 [published online ahead of print, 2022 Jan 7].
 N Eng J Med **2022.** doi:10.1056/NEJMcp2117115.
- Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis [published correction appears in PLoS Med 2021 Oct 13 ; 18(10):e1003825]. PLoS Med 2021 ; 18(8):e1003735.
 doi:10.1371/journal.pmed.1003735.
- Boum Y, Fai KN, Nikolay B, et al. Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study [published correction appears in Lancet Infect Dis 2021 Jun; 21(6):e148] [published correction appears in Lancet Infect Dis. 2021 Jul; 21(7):e182]. Lancet Infect Dis 2021; 21(8):1089-96. doi:10.1016/S1473-3099(21)00132-8.
- Baro B, Rodo P, Ouchi D, et al. Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison. J Infect 2021; 82(6):269 -275. doi: 10.1016/j.jinf.2021.04.009


- 16. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test (Panbio[™] COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. Clin Microbiol Infect **2021** ; 27(4):636.e1-636.e4. doi:10.1016/j.cmi.2020.12.022.
- Schuit E, Veldhuijzen IK, Venekamp RP, et al. Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. BMJ 2021 ; 374:n1676. doi:10.1136/bmj.n1676.
- Ministry of Health. Epidemiological Surveillance Guide: Public Health Emergency of National Importance due to Coronavirus Disease 2019. Available at: https://portalarquivos.saude.gov.br/images/af_gvs_coronavirus_6ago20_ajustes-finais-2.pdf.
- Drain P, Sulaiman R, Hoppers M, Lindner NM, Lawson V, Ellis JE. Performance of the LumiraDx Microfluidic Immunofluorescence Point-of-Care SARS-CoV-2 Antigen Test in asymptomatic adults and children [published online ahead of print, 2021 Oct 20]. Am J Clin Pathol 2021 ; aqab173. doi:10.1093/ajcp/aqab173.
- Kohmer N, Toptan T, Pallas C, et al. The comparative clinical performance of four SARS-CoV-2 rapid antigen tests and their correlation to infectivity in vitro. J Clin Med 2021 ; 10(2):328. doi:10.3390/jcm10020328.
- 21. Krüger LJ, Klein JAF, Tobian F, et al. Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx[™]: An antigen-detecting point-of-care device for SARS-CoV-2 [published online ahead of print, 2021 Aug 12]. Infection **2021** ; 1-12. doi:10.1007/s15010-021-01681-y.
- Bianco G, Boattini M, Barbui AM, et al. Evaluation of an antigen-based test for hospital point-ofcare diagnosis of SARS-CoV-2 infection. J Clin Virol 2021 ; 139:104838. doi:10.1016/j.jcv.2021.104838.


- 23. Fekete T. In adults and children, a rapid POC antigen test for COVID-19 (LumiraDx) had ≥97% sensitivity and specificity vs. RT-PCR. Ann Intern Med 2021 ; 174(7):JC82.
 doi:10.7326/ACPJ202107200-082.
- Karon BS, Donato LJ, Bridgeman AR, et al. Analytical sensitivity and specificity of four point of care rapid antigen diagnostic tests for SARS-CoV-2 using real-time quantitative PCR, quantitative droplet digital PCR, and a mass spectrometric antigen assay as comparator methods. Clin Chem 2021 ; 67(11):1545-1553. doi:10.1093/clinchem/hvab138.
- 25. Vogels CBF, Watkins AE, Harden CA, et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. Med (N Y) 2021; 2(3):263-280.e6.
 doi:10.1016/j.medj.2020.12.010.
- 26. Rodríguez Flores SN, Rodríguez-Martínez LM, Reyes-Berrones BL, Fernández-Santos NA, Sierra-Moncada EJ, Rodríguez-Pérez MA. Comparison between a standard and SalivaDirect RNA extraction protocol for molecular diagnosis of SARS-CoV-2 using nasopharyngeal swab and saliva clinical samples. Front Bioeng Biotechnol **2021**; 9:638902. doi:10.3389/fbioe.2021.638902.
- 27. Freppel W, Merindol N, Rallu F, Bergevin M. Efficient SARS-CoV-2 detection in unextracted oro-nasopharyngeal specimens by rRT-PCR with the Seegene Allplex[™] 2019-nCoV assay. Virol J 2020; 17(1):196. doi: 10.1186/s12985-020-01468-x.
- 28. World Health Organization. Antigen detection rapid diagnostic tests for coronavirus disease 2019 (COVID-19): master protocol for monitored implementation. Version 1.0. Geneva: WHO, 25 November 2020. Available at: <u>https://www.who.int/news-room/articles-detail/sars-cov-2-antigen-detecting-rapid-diagnostic-test-implementation-proposals</u>.
- Sauro, J. A practical guide to the System Usability Scale: Background, benchmarks, & best practices. Denver, CO: Measuring Usability LLC, 2011.

- Bangor, A., Kortum, PT, & Miller, JT. (2008). An empirical evaluation of the System Usability Scale. International Journal of Human-Computer Interaction 2008 ; 24(6), 574–94. https://doi.org/10.1080/10447310802205776.
- 31. United States Food and Drug Administration. Template for Developers of Antigen Tests. Available at: <u>https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas</u>. Version October 26 2020. Accessed 24 November 2020.
- 32. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition. Available at: <u>https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020/</u>. Accessed 10 September 2021.
- 33. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform 2009 ; Apr;42(2):377-81.
- 34. Routsias JG, Mavrouli M, Tsoplou P, Dioikitopoulou K, Tsakris A. Diagnostic performance of rapid antigen tests (RATs) for SARS-CoV-2 and their efficacy in monitoring the infectiousness of COVID-19 patients. Sci Rep 2021 ; 11:22863.
- 35. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis 2020 ; 39:1059–61.
- Yokota I, Sakurazawa T, Sugita J, et al. Performance of qualitative and quantitative antigen tests for SARS-CoV-2 using saliva. Infect Dis Rep 2021 ; 13(3):742-7. doi:10.3390/idr13030069.
- 37. Kritikos A, Caruana G, Brouillet R, et al. Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients: results of a prospective comparative trial (RESTART). Microorganisms 2021; 9(9):1910. doi:10.3390/microorganisms9091910.

- Igloi Z, Velzing J, Huisman R, et al. Clinical evaluation of the SD Biosensor saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients. PLoS One 2021 ; Dec 22;16(12):e0260894. doi:10.1371/journal.pone.0260894.
- 39. Chung S, Marlow S, Tobias N, et al. Lessons from countries implementing find, test, trace, isolation and support policies in the rapid response of the COVID-19 pandemic: a systematic review. BMJ Open 2021 ; 11(7):e047832. Doi: 10.1136.bmjopen-2020-047832.
- Smith RL, Gibson LL, Martinez PP, et al. Longitudinal assessment of diagnostic test performance over the course of acute SARS-CoV-2 infection. J Infect Dis 2021 ; 224(6).
 doi:10.1093/infdis/jiab337.
- 41. Revollo B, Blanco I, Soler P, et al. Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomized controlled trial. Lancet Infect Dis 2021;
 21(10):P1365 1372. doi: 10.1016/S1473-3099(21)00268-1.










Figure 3. Viral load value distributions across antigen tests among close contacts for a) the STANDARD Q Nasal Test and b) the STANDARD Q Saliva Test.




Figure 4. Descriptive plots for a subset of close contacts positive by the RT-PCR reference assay. Visit numbers are shown on the x-axis, and test results and symptom status are shown on the y-axis. Symptom status is presented independently of RT-PCR reference assay result.

a. A symptomatic individual with a low Ct value who tested positive by all assays at enrollment and met the stopping criteria upon the second visit.

b. An individual with no or mild symptoms whose reference positivity status fluctuated between visits, with high Ct values overall, and no positive point-of-care test results.




Figure 5. Time to positivity from time of first visit for close contacts with a positive NPS RT-PCR result (Ct<34) at any time. The blue line represents the proportion of NPS RT-PCR positive cases identified as positive by the point-of-care antigen test (STANDARD Q COVID-19 Ag test) on nasal samples, and the green line represents those identified by the reference NPS RT-PCR. Four different scenarios for RT-PCR result turnaround times are presented.

